Shimadzu Launches European Innovation Center
Shimadzu Corporation has opened a new European Innovation Center in Duisburg, Germany. The new facility will merge Shimadzu’s state-of-the-art analytical technologies with prominent topics, market expertise, and scientific research guided by some key opinion leaders.
Photo Credit: Lewis Botcherby
Shimadzu Corporation has opened a new European Innovation Center in Duisburg, Germany. The new facility will merge Shimadzu’s state-of-the-art analytical technologies with prominent topics, market expertise, and scientific research guided by some key opinion leaders.
Scientists from well-known universities are cooperating with Shimadzu on this new venture, including Luigi Mondello, University of Messina, Italy; Erich Leitner, Graz University of Technology, Austria; Uwe Karst, University of Münster, Germany; Franck Saint-Marcoux, University Hospital of Limoges, France; Gerard Hopfgartner, University of Geneva, Switzerland; and Frank Walther, Technical University of Dortmund, Germany.
The new facility will focus on four key scientific areas: clinical applications, imaging technology, food, and composites, with an emphasis being placed on the development of new methods, tools, techniques, diagnostics, and solutions.
“It is [because of] our commitment to society and [to] ourselves that Shimadzu remains dedicated in our pursuit of technology and [the] accumulation of knowledge,” said Dr. Teruhisa Ueda, President and CEO of Shimadzu Corporation.
The new facility follows in the footsteps of Shimadzu’s other Innovations Centers located in Maryland, USA, Beijing, China, and Singapore.
For more information on Shimadzu’s new Innovation Center please visit: https://www.shimadzu.eu/launch-shimadzu-european-innovation-center
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
